Trial reportArchives of neurology2011
Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative.
Trial report in Archives of neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00106899 (Alzheimer's Disease Neuroimaging Initiative), which is not on this map. Cited by 75 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Alzheimer's Disease Neuroimaging Initiative
Who cites it
75 citing papers in PubMed, 6 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2023Pooled it
- Testing whether the progression of Alzheimer's disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data.Alzheimer's research & therapy · 2020Pooled it
- Memantine for dementia.The Cochrane database of systematic reviews · 2019Pooled it
- Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.JAMA network open · 2018Pooled it
- Smoking and increased Alzheimer's disease risk: a review of potential mechanisms.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2014Pooled it
- Mild cognitive impairment and dementia: the importance of modifiable risk factors.Deutsches Arzteblatt international · 2011Pooled it
- Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.Journal of Alzheimer's disease : JAD · 2018Trial
- Treatment Effects of Cholinesterase Inhibitors in Alzheimer's Disease: a Causal Machine Learning Approach.medRxiv : the preprint server for health sciences · 2026Article
- The impact of cholinesterase inhibitors on cognitive trajectories in mild cognitive impairment patients based on amyloid beta status.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Protective Effects of Bifidobacterium Breve MCC1274 as a Novel Therapy for Alzheimer's Disease.Nutrients · 2025Review
- Mechanisms to medicines: navigating drug repurposing strategies in Alzheimer's disease.Frontiers in aging neuroscience · 2025Review
- Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes.Alzheimer's research & therapy · 2024Article
- Protein restriction slows the development and progression of pathology in a mouse model of Alzheimer's disease.Nature communications · 2024Article
- Protein restriction slows the development and progression of Alzheimer's disease in mice.Research square · 2024Article
- Pediococcus pentosaceus LAB6- and Lactiplantibacillus plantarum LAB12-Derived Cell Free Supernatant Inhibited RhoA Activation and Reduced Amyloid-Β In Vitro.Probiotics and antimicrobial proteins · 2024Article
- Moderation of Amyloid-β Deposition on the Effect of Cholinesterase Inhibitors on Cognition in Mild Cognitive Impairment.Journal of Alzheimer's disease : JAD · 2024Article
- Frameworks for estimating causal effects in observational settings: comparing confounder adjustment and instrumental variables.BMC medical research methodology · 2023Review
- Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2023Article
- The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea.Naunyn-Schmiedeberg's archives of pharmacology · 2022Article
- The Relationship Between Prior Cancer Diagnosis and All-Cause Dementia Progression Among US Adults.Journal of Alzheimer's disease : JAD · 2022Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectivesTo assess the clinical characteristics and course of patients with mild cognitive impairment (MCI) and mild Alzheimer disease (AD) treated with cholinesterase inhibitors (ChEIs) and memantine hydrochloride.
designCohort study.
settingThe 59 recruiting sites for the Alzheimer's Disease Neuroimaging Initiative (ADNI).
participantsOutpatients with MCI and AD in ADNI.
main outcome measuresThe AD Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR) scale, and Functional Activities Questionnaire (FAQ).
resultsA total of 177 (44.0%) of 402 MCI patients and 159 (84.6%) of 188 mild-AD patients were treated with ChEIs and 11.4% of MCI patients and 45.7% of AD patients with memantine at entry. Mild-cognitive-impairment patients who received ChEIs with or without memantine were more impaired, showed greater decline in scores, and progressed to dementia sooner than patients who did not receive ChEIs. Alzheimer-disease patients who received ChEIs and memantine took them longer, were more functionally impaired, and showed greater decline on the MMSE and CDR (but not on the ADAS-cog or FAQ) than those who received ChEIs only.
conclusionsAcademic physicians frequently prescribe ChEIs and memantine earlier than indicated in the US Food and Drug Administration-approved labeling to patients who are relatively more severely impaired or who are rapidly progressing toward cognitive impairment. The use of these medications in ADNI is associated with clinical decline and may affect the interpretation of clinical trial outcomes. STUDY REGISTRATION: clinicalTrials.gov Identifier: NCT00106899.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.